COMMUNIQUÉS West-GlobeNewswire

GENFIT : GNS561 montre une activité antitumorale prometteuse en combinaison thérapeutique
10/12/2025
Données préliminaires très encourageantes de l’étude de Phase 1b en cours évaluant le médicament expérimental GNS561 associé à un inhibiteur de MEK (MEKi) dans le cholangiocarcinome (CCA) avec mutation KRAS, [...]
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy
10/12/2025
Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated cholangiocarcinoma (CCA), positioning this novel combination as a [...]
EssilorLuxottica va collaborer avec la fondation Chips-IT pour accélérer dans les lunettes connectées
10/12/2025
EssilorLuxottica va collaborer avec la fondation Chips-IT pour accélérer dans les lunettes connectées Paris, France (10 décembre 2025) – EssilorLuxottica a annoncé aujourd'hui une collaboration avec la fondation Chips- [...]
EssilorLuxottica joins forces with Fondazione Chips-IT to accelerate the future of smart eyewear
10/12/2025
EssilorLuxottica joins forces with Fondazione Chips-IT to accelerate the future of smart eyewear Paris, France (10 December 2025) – EssilorLuxottica announces it is joining forces with Fondazione Chips-IT, Italy’s [...]
Persephone Biosciences Announces Publication in Cell Host & Microbe Highlighting the Critical Need to Restore Bifidobacterium in the Infant Gut Microbiome
10/12/2025
- Evidence shows infant microbiome trajectories established in the first months of life persist, shaping immune function and allergy risk into childhood - - Targeted early-life probiotic interventions using B. infantis [...]
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
10/12/2025
SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Kane Biotech Receives Health Canada Approval for revyve® Antimicrobial Wound Gel Spray
10/12/2025
WINNIPEG, Manitoba, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that Health Canada has approved its revyve ® Antimicrobial Wound Gel Spray [...]
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
10/12/2025
Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ProMIS on track to complete enrollment in PRECISE-AD trial in Alzheimer’s disease [...]
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
10/12/2025
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case exceeding objective [...]
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
10/12/2025
BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium (SABCS ® ) Phase 3 study of Bria-IMT™ plus immune check point inhibitor (CPI) continues to support biomarkers to [...]
Avance Clinical Launches Diversity in STEM Scholarships Across Australia and North America
10/12/2025
ADELAIDE, Australia, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Avance Clinical, the award-winning global CRO for biotechs, has announced the launch of its new Diversity in STEM Scholarships , a global initiative designed to [...]
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
10/12/2025
CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
10/12/2025
VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trial VTP-1000 was well-tolerated with no treatment-related SAEs The MAD [...]
Accrete Health Partners Launches Partnership with Atalan to Co-develop Groundbreaking Patient Experience Intelligence Module
10/12/2025
Strategic Co-Development Partnership Expands Relationship between Bon Secours Mercy Health and Atalan to Unify Workforce and Patient Experience Analytics PHILADELPHIA, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Atalan , the [...]
DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility
10/12/2025
Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in 10–15 [...]
PetMeds Announces Holiday Collection: Wellness-Focused Gifts for Pets and the People Who Love Them
10/12/2025
DELRAY BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the “Company”), today unveiled its new Holiday Collection, a curated selection [...]
Ajax Therapeutics Receives Orphan Drug Designation from the U.S. FDA for AJ1-11095 for the Treatment of Myelofibrosis
10/12/2025
AJ1-11095 is a first-in-class Type II JAK2 inhibitor currently in a Phase 1 study for the treatment of patients with myelofibrosis, previously treated with a Type I JAK2 inhibitor NEW YORK and CAMBRIDGE, Mass., Dec. 10 [...]
SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
10/12/2025
U.S. Losartan market totals $245M annually with 71M prescriptions COMMACK, NY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical [...]
24/7 Market News- Kraig Labs Breakthrough Science is Pivoting to Scalable Business
10/12/2025
How Decades of Innovation Are Converging for Commercial Spider Silk Success DENVER, Dec. 10, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial [...]

Pages